To downregulate and inhibit Wnt16, liposome-protamine-hyaluronic acid NPs carrying anti-Wnt16 siRNAs were tailored to enhance efficiency of cisplatin-containing LCP NPs within the stroma-rich environment of a bladder cancer model and foster cisplatin responses (Fig. 3d(ii)). The gene discussed is WNT16; the disease is urinary bladder carcinoma.